Acidente Vascular Cerebral Isquêmico em paciente jovem devido à deficiência de proteína S no contexto da distrofia muscular - relato de caso

A 19-year-old woman with a 6-year history, consisting of frequent falls and weakness due to loss of strength in the lower extremities. During the last 10 hours, she presented a sudden episode of left hemiplegia, deviation of the labial commissure to the right, dysarthria and four emetic episodes. She was diagnosed with an ischemic stroke caused by a deficiency of the S-protein and, in addition, a muscular dystrophy. This case report may indicate a relationship between muscular dystrophy and ischemic stroke caused by a protein S deficiencyMujer de 19 años con historia de 6 años de evolución consistente en caídas frecuentes y debilidad debido a la pérdida de fuerza en los miembros inferiores. Durante las últimas 10 horas, presentó un episodio repentino de hemiplejia izquierda, desviación de la comisura labial a la derecha, disartria y cuatro episodios eméticos. Ella fue diagnosticada con accidente cerebrovascular isquémico causado por una deficiencia de la proteína S y además con distrofia muscular. Este reporte de caso puede indicar una relación entre la distrofia muscular y el accidente cerebrovascular isquémico causado por una deficiencia de proteína S.Mulher de 19 anos com história de 6 anos, consistindo de quedas frequentes e fraqueza devido à perda de força nas extremidades inferiores. Durante as últimas 10 horas, apresentou episódio súbito de hemiplegia esquerda, desvio da comissura labial à direita, disartria e quatro episódios eméticos. Ela foi diagnosticada com um acidente vascular cerebral isquêmico causado por uma deficiência da proteína S e, além disso, uma distrofia muscular. Este relato de caso pode indicar uma relação entre distrofia muscular e acidente vascular cerebral isquêmico causado por deficiência de proteína

Scoping review on population pharmacokinetics of vancomy- 2 cin in hospitalized adults

14 páginasVancomycin is an effective first-line therapy in MRSA infection, however, achieving an 13 appropriate serum concentration is challenging. Population pharmacokinetics can offer assistance 14 to the clinician in the selection of better regimen dosing and improve effectiveness and safety out- 15 comes. This scoping review aims to outline the evidence in population pharmacokinetic models in 16 non-critical adults hospitalized from 1980 to 2021 and describe the principal software and covaria- 17 bles used in this. A total of 209 papers were fully screened. Finally, we included 17 articles con- 18 ducted in different locations around the world. This review identified 13 retrospective articles and 19 4 prospective, 5 describing the use in a general population with gram-positive bacterial infection, 20 11 evaluated special populations (older, obese, and cancer patients), and 1 mixed population. The 21 main parameters in the models were renal clearance and volume of distribution. The principal co- 22 variables that affected the models were creatinine clearance and weight. All studies use internal 23 validation methods, and three of them used an external validation group. This scoping review high- 24 lights the principal information of different population pharmacokinetic models and the heteroge- 25 neity in the parameters and methods of evaluation. These methods can be used to guide the dosing 26 regimen in different subpopulations. However, it is imperative to define the best fit in every popu- 27 lation and conduct an experiment due to the high variability in the present studies.Especialización en Farmacología ClínicaEspecialista en Farmacología Clínic